Agfa-Gevaert NV AGFB.BR
Composite 43/100; the shares have moved about 42% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 12/100 — a strong mark against it.
Valuation ranks 80/100 — a strong point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Growth ranks 12/100 — a strong mark against it. Momentum ranks 24/100 — a strong mark against it. Quality ranks 29/100 — a moderate mark against it.
What the company does Agfa-Gevaert NV designs analog and digital imaging systems for healthcare, printing, industrial inkjet, hydrogen membranes, and specialty materials. Its SmartXR platform supports radiography workflow optimization, while its print division serves signage, packaging, and electronics sectors.
Key financials Agfa reports negative profitability: ROE -18.1%, ROA -0.1%, and net margin -5.8%. Revenue fell -2.5% while EPS surged 533.3%. Gross margin stands at 30.6%, but operating margin is -1.7%. Debt/equity is 0.80 with net debt/EBITDA at 8.00.
Stock health The stock shows weak quality (Sideravia Quality 33.3) but attractive valuation (Valuation 80.7). Momentum is poor (Momentum 12.8) with a -65% decline over 12 months and RSI(14) at 40.20. Piotroski F-Score is 5/9 and Altman Z is 2.51.
Price vs fair value The stock trades at a discount of 15.80% versus our fair-value estimate of 0.44 and a discount of 84.21% versus the analyst 12-month target of 0.70. - Trading at a discount of 15.80% to fair-value estimate of 0.44 (Fair Value & Analyst View) - Trading at a discount of 84.21% to analyst target of 0.70 (Fair Value & Analyst View) - Negative profitability with ROE -18.1% and net margin -5.8% (Key Financials) - Weak momentum with 12-month return of -65% and RSI 40.20 (Stock Health) - High valuation percentile of 80.7 despite poor fundamentals (Sideravia Score)
Looking forward Forward P/E is 13.04, suggesting potential value if profitability improves. FCF yield is 132.9%, indicating strong cash generation relative to market cap. Growth remains challenged with revenue down -2.5%, but EPS growth of 533.3% reflects one-time effects.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.